Clinical Trial Results 20 November 2026

Nov 20, 2026 | Clinical Trials

Image Source: Image generated using Google Gemini
Written by: LSDN Editorial Team
On behalf of: Life Science Daily News

Clinical trial results 20 November 2026 span acute myeloid leukaemia, type 3 Gaucher disease, bladder cancer, depression and Alzheimer’s disease.

SELLAS Life Sciences’ galinpepimut-S met its overall survival primary endpoint in acute myeloid leukaemia. The FDA approved Sanofi’s venglustat (Infilbray) for neurological manifestations of type 3 Gaucher disease. CG Oncology’s cretostimogene grenadenorepvec met its primary endpoint in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer. Helus Pharma’s HLP003 met its primary endpoint as an add-on treatment in major depressive disorder. In early Alzheimer’s disease, AriBio’s AR1001 met its primary objective in a prespecified monotherapy population. It did not reach significance in the overall population. Here, Life Science Daily News brings you the week’s most significant readouts.

Galinpepimut-S Meets Its Overall Survival Primary Endpoint in the Phase 3 REGAL Trial

SELLAS Life Sciences announced topline REGAL results for galinpepimut-S (GPS) on 17 November. The Phase 3 trial met its primary endpoint of overall survival in acute myeloid leukaemia (AML). Patients were in second or later complete remission. Median overall survival was 24.0 months with GPS against 14.7 months with best available treatment. The hazard ratio was 0.59 (p=0.035, two-sided). SELLAS describes this as a 41 per cent reduction in the risk of death. The analysis was triggered by 80 deaths, the event count prespecified in the statistical analysis plan. The release does not give a confidence interval. Treatment-related adverse events were mostly grade 1 or 2, most commonly injection site reactions. No new safety signals were reported. Transplant rates were low and balanced between the arms.

The global, randomised, open-label trial (NCT04229979) enrolled 126 patients, randomised 1:1. All had reached second or later complete remission, or complete remission with insufficient platelet recovery, after salvage therapy. All were also ineligible for, or unable to undergo, allogeneic stem cell transplant. The comparator was investigator’s choice of best available treatment. Options were observation, a hypomethylating agent, venetoclax or low-dose cytarabine, alone or in combination. GPS is a peptide vaccine targeting WT1, a protein expressed in AML and many other cancers. It contains four WT1-derived peptides designed to provoke CD4+ and CD8+ T-cell responses across HLA types. It is given as maintenance therapy and was licensed from Memorial Sloan Kettering Cancer Center. SELLAS plans to discuss an accelerated filing strategy with the FDA. It targets a Biologics License Application in the first half of 2027. Secondary analyses are still under way, and the data have not been peer-reviewed.

Venglustat (Infilbray) Is Approved by the FDA for Neurological Manifestations of Type 3 Gaucher Disease

Sanofi announced the FDA approval of venglustat (Infilbray) on 18 November. It is approved for neurological manifestations of type 3 Gaucher disease (GD3). The decision came a week ahead of the 25 November target action date. The approval covers adults and paediatric patients weighing at least 15 kg. Sanofi describes Infilbray as the first medicine to treat the neurological manifestations of GD3. The approval rests on the Phase 3 LEAP2MONO trial against the enzyme replacement therapy (ERT) imiglucerase. Venglustat was superior on the primary endpoint at week 52 (p=0.0137). That endpoint was a prespecified global test of two measures. One was a four-item modified Scale for the Assessment and Rating of Ataxia (mSARA). The other was the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score. The release does not report the separate mSARA or RBANS results. Diarrhoea, splenomegaly and nausea each occurred in 14 per cent on venglustat. The rates on imiglucerase were 0, 0 and 5 per cent.

LEAP2MONO (NCT05222906) was a double-blind, double-dummy, active-comparator study. It randomised 43 patients aged 12 and over 1:1 to once-daily oral venglustat or intravenous imiglucerase every two weeks. All had received ERT for at least three years and had met systemic treatment goals. Venglustat is an oral glucosylceramide synthase inhibitor designed to act across the blood-brain barrier. GD3 is a chronic neuronopathic form of Gaucher disease, with cognitive deficits and ataxia among its neurological features. The label carries warnings for suicidal ideation and behaviour, lens opacification in paediatric patients and embryofoetal toxicity. Venglustat held Breakthrough Therapy, Rare Pediatric Disease and Fast Track designations and received Priority Review. It is under review in the EU, Japan and other jurisdictions, and the open-label phase of LEAP2MONO continues. LSDN follows pending decisions in its FDA drug approval decisions tracker.

Cretostimogene Meets Its Primary Endpoint in the Phase 3 PIVOT-006 Trial

CG Oncology reported topline PIVOT-006 results for cretostimogene grenadenorepvec on 16 November. Adjuvant intravesical cretostimogene after complete tumour resection met the primary endpoint of recurrence-free survival against surveillance. The population had intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The hazard ratio was 0.32 (95 per cent CI 0.23 to 0.45; p<0.0001). The company reports this as a 68 per cent reduction in the risk of recurrence. It says the benefit held in both high-grade and low-grade disease. Median recurrence-free survival for each arm is not given. Median follow-up was 17 months at the 26 October 2026 data cut. No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations were reported.

The randomised, open-label trial (NCT06111235) enrolled 367 patients at about 90 sites in the United States and Canada. Eligible disease included recurrent, multifocal or large low-grade Ta tumours and solitary high-grade Ta tumours of 3 cm or less. Low-grade T1 disease was also eligible. Cretostimogene is an oncolytic immunotherapy delivered into the bladder. Its Fast Track and Breakthrough Therapy designations relate to BCG-unresponsive NMIBC. After FDA feedback, CG Oncology is broadening its first Biologics License Application, in BCG-unresponsive disease. It will now also include high-grade papillary-only tumours, with completion expected by the end of March 2027. A second application, for the PIVOT-006 population, is expected in the second quarter of 2027. The data will be presented as a late-breaker at the Society of Urologic Oncology Annual Meeting on 2 December. They are not yet peer-reviewed.

HLP003 Meets Its Primary Endpoint in the Phase 3 APPROACH Study in Major Depressive Disorder

Helus Pharma announced topline APPROACH results for HLP003 on 16 November. HLP003 was given as an add-on to existing antidepressant treatment. It met the primary endpoint, change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 6. Scores fell by 19.5 points with HLP003 and 11.9 points with placebo. The difference was 7.6 points (p<0.0001). At week 12, the key secondary endpoint, the difference was 7.0 points (p<0.0001). Response was defined as a MADRS reduction of at least 50 per cent. At week 6 it was 56.3 per cent against 28.2 per cent. Remission was 50.9 per cent against 18.2 per cent. A difference of 5.0 points was already present at day 2 (p=0.0013). Most adverse events were mild to moderate and mainly limited to the day of dosing. Three treatment-related serious adverse events occurred with HLP003.

The randomised, double-blind, placebo-controlled trial enrolled 222 adults with moderate to severe major depressive disorder. Of these, 112 received HLP003 and 110 received placebo. All continued a stable antidepressant dose, and baseline MADRS scores were 32.7 and 33.8. The release gives no trial identifier and does not describe the dose or the number of dosing sessions. HLP003 is a deuterated form of psilocin. Helus describes it as a serotonergic agonist designed to activate pathways believed to promote neuroplasticity. It holds FDA Breakthrough Therapy designation. A second pivotal study, EMBRACE, is due to read out in the fourth quarter of 2027. The EXTEND study will assess long-term safety, durability and redosing. The release does not say how multiplicity across the day 2, week 6 and week 12 analyses was handled. The full dataset has not been published.

AR1001 Meets Its Primary Objective in the Monotherapy Population but Not the Overall Population in Phase 3 POLARIS-AD

AriBio reported topline POLARIS-AD results for AR1001 on 16 November. The data were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. The primary endpoint was change in Clinical Dementia Rating Sum of Boxes (CDR-SB) at week 52. It was tested in two prespecified populations, and success required significance in at least one. In the overall population of 1,535 patients, the difference against placebo was 0.11 points (p=0.4015). That was not statistically significant. The monotherapy population comprised 604 patients not taking an acetylcholinesterase inhibitor or memantine. There, the difference was 0.44 points (p=0.0266). AriBio describes this as a 31 per cent slowing of decline. In that population, ADAS-Cog 13 was not significant (p=0.0798) and MMSE was nominally significant (p=0.0232). Adverse events led to discontinuation in 5.2 per cent on AR1001 against 1.7 per cent on placebo. There were 4 fatal adverse events against 2. Serious adverse events were balanced, at 10.0 per cent against 9.8 per cent.

The global, randomised, double-blind trial (NCT05531526) ran at about 230 sites in 13 countries. Participants with early Alzheimer’s disease received AR1001 30 mg or placebo once daily for 52 weeks. AR1001 is an oral phosphodiesterase 5 (PDE5) inhibitor designed to cross the blood-brain barrier and enhance cGMP signalling. Cerebrospinal fluid (CSF) cGMP rose against placebo in both populations, which the company says supports target engagement. CSF p-tau217 numerically favoured AR1001 in both populations. It reached p=0.0402 in the monotherapy population only (overall p=0.1784). The amyloid beta 42/40 ratio did not change. A total of 1,284 participants entered an open-label extension that runs to the third quarter of 2027. AriBio will discuss the complete findings with the FDA. Global principal investigator Sharon Sha said the secondary and biomarker findings warrant further evaluation alongside the overall population result. LSDN’s neurodegeneration pipeline overview set out the field ahead of this readout.

Looking Ahead

This week’s clinical trial results 20 November 2026 include two positive Phase 3 oncology readouts with different strengths of evidence. Cretostimogene’s PIVOT-006 result rests on a hazard ratio of 0.32 with a narrow confidence interval in 367 patients. That comparison was against surveillance, with 17 months of median follow-up. REGAL gives galinpepimut-S a survival benefit in a population with few options. It rests, however, on 126 patients in an open-label trial, with p=0.035 and no published confidence interval. Venglustat’s approval is, by Sanofi’s account, the first for the neurological manifestations of GD3. It is built on a 43-patient trial whose component results are not yet public.

HLP003 separated from placebo on every reported measure. The release, however, leaves the dose and the multiplicity strategy undescribed. The second pivotal study is also a year away. AR1001 is the week’s most mixed result. It met its prespecified success rule only through the monotherapy population. The overall population showed almost no difference from placebo. Discontinuations and deaths were numerically higher on treatment, though serious adverse events were balanced. Whether the monotherapy signal holds will depend on further data and on the FDA’s view. Life Science Daily News will continue to cover the readouts that matter across the global life sciences pipeline.

Read the 13 November 2026 clinical trials roundup.

    References: All sources are linked within the article above.
    This clinical trials roundup is produced by the Life Science Daily News editorial team. All stories are selected and written independently. All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions.

    Articles that may be of interest

    Clinical Trial Results 13 November 2026

    Clinical Trial Results 13 November 2026

    Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...

    read more
    From GLP-1 Trial Results to the Follow-Up Visit

    From GLP-1 Trial Results to the Follow-Up Visit

    A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

    read more
    Clinical Trial Results 6 November 2026

    Clinical Trial Results 6 November 2026

    The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

    read more
    ObesityWeek 2026 Preview: The Data to Watch in Washington

    ObesityWeek 2026 Preview: The Data to Watch in Washington

    ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...

    read more

    Articles that may be of interest

    Clinical Trial Results 13 November 2026

    Clinical Trial Results 13 November 2026

    Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...

    read more
    From GLP-1 Trial Results to the Follow-Up Visit

    From GLP-1 Trial Results to the Follow-Up Visit

    A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

    read more
    Clinical Trial Results 6 November 2026

    Clinical Trial Results 6 November 2026

    The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

    read more
    ObesityWeek 2026 Preview: The Data to Watch in Washington

    ObesityWeek 2026 Preview: The Data to Watch in Washington

    ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...

    read more